Industry News
Pharmaceutical Industry News
Two Telehealth Executives Sentenced for Scheme to Distribute Adderall
The Justice Department said Done Global’s clinicians signed prescriptions for the stimulant drug, which is used to treat A.D.H.D., every 30 seconds.
Bleeding disorder patient groups…
Bleeding disorder patient groups put Sobi, Roche and Novo Nordisk on the podium in 2025/2026's corporate reputation rankings from PatientView.
Aiming to streamline the…
Aiming to streamline the compensation process for people claiming harm from COVID-19 vaccines, Robert F. Kennedy Jr.’s Department of Health and Human Services is gearing up to draft a list of injuries believed to be
The surprising failure of…
The surprising failure of AstraZeneca and Ionis in a key phase 3 trial of Wainua in patients with ATTR-CM has sent the companies' shares tumbling, while those of their competitors are soaring. The CARDIO-TTRansform study
In a first for the neurotoxin…
In a first for the neurotoxin market, Ipsen announced Thursday that its Dysport has hit the goals in two phase 3 trials for the prevention of both episodic and chronic migraines.
When launching a drug as big as…
When launching a drug as big as semaglutide, even as a generic, expectations are immense. Any fumble by a manufacturer can take a toll.
Novo Nordisk is running an…
Novo Nordisk is running an exhibition in central London designed to start a dialogue on obesity and help remove the stigma surrounding the condition.
BioNTech is on the verge of…
BioNTech is on the verge of returning to its oncology roots with potentially its first commercial cancer drug. Yet, to Chief Commercial Officer Annemarie Hanekamp, the upcoming launch is less of a standalone milestone and
The FDA took issue with multiple…
The FDA took issue with multiple claims describing Vyepti's efficacy listed on Lundbeck's healthcare provider webpage for the drug.
On the heels of a European…
On the heels of a European Commission probe into whether Sanofi “disparaged” one of its flu vaccine rivals in marketing its own shot, the EC is lining up a “market test” to solicit feedback on
Lawmakers Target the Power of Health Insurance Giants
UnitedHealth Group, CVS Health and Cigna are battling efforts to break up their control over prescription drugs.
As AI raises the stakes, leaders…
As AI raises the stakes, leaders need more than data. They need the readiness to turn insight into action.
How GLP-1s Feed Our Sick Culture
For women, they’re a depressingly rational choice.
CureDuchenne’s “A Cure Can’t Wait”…
CureDuchenne's "A Cure Can't Wait" serves as a public service announcement reminding viewers that "the clock is ticking" for patients and families with the rare progressive disease Duchenne muscular dystrophy.
Amid an ongoing expansion of…
Amid an ongoing expansion of China’s volume-based procurement (VBP) scheme to lower drug costs, the Chinese government has singled out a fraud case involving a foreign originator drug in a warning to the industry.
After thriving in the market for…
After thriving in the market for more than a decade as the only treatment for Dupuytren's contracture and Peyronie’s disease, Keenova Therapeutics’ Xiaflex has excelled in a phase 3 trial that could set up the
After pledging earlier this year…
After pledging earlier this year to bolster its drug substance capabilities in Central Europe, German chemical company Evonik is turning its attention to the U.S.
Catalent is shedding one of its…
Catalent is shedding one of its U.K. manufacturing facilities as it inks a separate partnership deal to advance a new gene therapy, expanding in certain areas while scaling back in others.
Allergan Aesthetics on Tuesday…
Allergan Aesthetics on Tuesday welcomed Girls Inc. participants to a panel and tour at its Allergan Medical Institute in Orange County, CA.
In biopharmaceutical R&D,…
In biopharmaceutical R&D, where fewer than 1 in 10 development programs ultimately reach approval, risk assessment remains central to portfolio strategy and investment decisions.